BeiGene
BeiGene is a life sciences biotechnology company.
BeiGene, founded in October, 2010 and headquartered in Beijing, is an anti-tumor drug developer. The founder is Wu Xiaobin. Listed on the HKEX on August 8, 2018, the company's major shareholders are Beigene, Ltd.. Rivals that have direct and indirect competition with BeiGene include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
Singaporean Prime Minister Lee Hsien Loong meets with weifenghe
Baiji Shenzhou PD-1 monoclonal antibody baizean ® The ninth indication was obtained and the first-line treatment for nasopharyngeal carcinoma was approved
A new breakthrough in the first-line treatment of advanced esophageal cancer: PD-1 monoclonal antibody baizean ® Global phase 3 clinical trials reached the primary end point
Research
Consumer Staples, Healthcare, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Baiji China: the tentative list is a normal step and will not affect the listing of the company on NASDAQ
Ministry of agriculture and rural areas: implement the ten-year fishing ban on the Yangtze River in 2022 and promote the conservation of aquatic biological resources
Hillhouse Q4 position: increased holdings of ideal automobile and Xiaopeng automobile sea, and ideal automobile rushed into the top ten
Hong Kong Pharmaceutical stocks generally rose, with Cinda biology up nearly 6%
54% off! Pamipali, the first PARP inhibitor approved for the treatment of platinum sensitive and platinum resistant recurrent ovarian cancer, was included in Medicare